July 17, 2025

FDA Approves Shingrix Prefilled Syringe Option

The FDA has approved a new prefilled syringe presentation of Shingrix to simplify herpes zoster vaccination for eligible adult patients.

Conexiant

July 16, 2025

New Guidelines Target Preventive Gaps in Inflammatory Bowel Disease

New clinical recommendations detail updated vaccination and screening protocols to reduce infection and cancer risks in adults with inflammatory bowel disease, particularly those on immune-modifying therapies.

Conexiant

July 10, 2025

HHS Scraps Preventive Care Panel Meeting

HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.

Conexiant

July 10, 2025

Cervical Cancer Risk Remains High After 65

A new large-scale study of over 2 million women raises questions about age cutoffs in cervical cancer screening policies after findings reveal that women aged 65 and older face significantly higher rates of cervical cancer-related abnormalities and high-risk HPV infections.

Conexiant

July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

June 26, 2025

Medical Groups Unite on Vaccine Policy

Major medical associations jointly reaffirm commitment to respiratory virus vaccines amid federal immunization review process changes.

Conexiant

June 24, 2025

Exam Shift Spurs National Rights Battle

Democratic AGs push to relocate OB-GYN exams from Texas, citing threats to reproductive and gender-affirming care under state abortion bans.

KFF Health News

June 24, 2025

HSV-1 Restructures Human Genome via Hijacking

Researchers uncovered how herpes simplex virus type 1 reprograms human chromatin structure by hijacking transcriptional machinery, potentially revealing a new antiviral target.

Conexiant

June 20, 2025

FDA Approves First Twice-Yearly Injectable PrEP

FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.

Conexiant